Patents by Inventor Hwa-Sil Kim

Hwa-Sil Kim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted pyrazoles as LRRK2 inhibitors
    Patent number: 11370796
    Abstract: A pyrrolo(pyrazolo)pyrimidine compound of Formula 1, a pharmaceutically acceptable salt, a hydrate, a solvate, a prodrug, and an isomer, and pharmaceutical compositions containing the compound are disclosed. The compound of Formula 1 shows excellent LRRK2 inhibitory activity.
    Type: Grant
    Filed: December 3, 2018
    Date of Patent: June 28, 2022
    Assignee: OSCOTEC INC.
    Inventors: Jung-Ho Kim, Jang-Sik Choi, Song-Eun Park, Hwa Sil Kim, Dong-Sik Jung, Jong-Sung Koh, Se-Won Kim, Jaekyoo Lee
  • PYRROLO(PYRAZOLO)PYRIMIDINE DERIVATIVE AS LRRK2 INHIBITOR
    Publication number: 20210363144
    Abstract: The present invention relates to a pyrrolo(pyrazolo)pyrimidine derivative having efficacy as an LRRK2 inhibitor, a preparation method therefor, and a pharmaceutical composition for preventing or treating degenerative brain diseases, containing the same.
    Type: Application
    Filed: December 3, 2018
    Publication date: November 25, 2021
    Applicant: OSCOTEC INC.
    Inventors: Jung-Ho KIM, Jang-Sik CHOI, Song-Eun PARK, Hwa Sil KIM, Dong-Sik JUNG, Jong-Sung KOH, Se-Won KIM, Jaekyoo LEE
  • 1,3-dioxoisoindole derivatives having selective antagonism of T-type calcium channel
    Patent number: 7319098
    Abstract: The present invention relates to 1,3-dioxoisoindole derivatives of Formula (1) or pharmaceutically acceptable salts thereof, a preparation method thereof and use thereof as a T-type calcium channel antagonist, based on the fact that 1,3-dioxoisoindole derivatives of Formula (1) show selective antagonistic activity against T-type calcium channel, thus being effective in treating brain diseases, cardiac diseases and neurogenic pains: wherein R1 is a phenyl or a benzyl group, optionally substituted with a moiety selected from the group consisting of a halogen atom, a C1-C6 alkoxy, a C1-C6 alkyl, and a cyano group; R2 is a heterocyclic group selected from the group consisting of piperidinyl, pyrrolidinyl, morpholinyl, and piperazinyl groups, wherein the heterocyclic group is optionally substituted with a C1-C6 alkyl group; and n is 1 or 2.
    Type: Grant
    Filed: November 16, 2006
    Date of Patent: January 15, 2008
    Assignee: Korea Institute of Science and Technology
    Inventors: Yong Seo Cho, Hyunah Choo, Ae Nim Pae, Joo Hwan Cha, Hun Yeong Koh, Hwa-Sil Kim, Hyewhon Rhim, Seon Hee Seo
  • 1,3-DIOXOISOINDOLE DERIVATIVES HAVING SELECTIVE ANTAGONISM OF T-TYPE CALCIUM CHANNEL
    Publication number: 20070259867
    Abstract: The present invention relates to 1,3-dioxoisoindole derivatives of Formula (1) or pharmaceutically acceptable salts thereof, a preparation method thereof and use thereof as a T-type calcium channel antagonist, based on the fact that 1,3-dioxoisoindole derivatives of Formula (1) show selective antagonistic activity against T-type calcium channel, thus being effective in treating brain diseases, cardiac diseases and neurogenic pains: wherein R1 is a phenyl or a benzyl group, optionally substituted with a moiety selected from the group consisting of a halogen atom, a C1-C6 alkoxy, a C1-C6 alkyl, and a cyano group; R2 is a heterocyclic group selected from the group consisting of piperidinyl, pyrrolidinyl, morpholinyl, and piperazinyl groups, wherein the heterocyclic group is optionally substituted with a C1-C6 alkyl group; and n is 1 or 2.
    Type: Application
    Filed: November 16, 2006
    Publication date: November 8, 2007
    Inventors: Yong Seo Cho, Hyunah Choo, Ae Nim Pae, Joo Hwan Cha, Hun Yeong Koh, Hwa-Sil Kim, Hyewhon Rhim, Seon Hee Seo